Tests a finger-prick glucose test at home for early diabetes checks
Tests a home finger-prick version of a glucose tolerance test in children.
Key facts
- Who runs it
- University of Oxford
- Where
- Cardiff, London, Nottingham, and Oxford, United KingdomSee the 4 sites
- Trial code
- Registry title
- Capillary OGTT Study
- Status
- Recruiting
- People taking part
- 135 people, planned
- Started
- 29 Feb 2024
- Expected to end
- 31 Aug 2027
- Type of study
- Observational, 5 groups
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people under 18 who are having or agree to have an oral glucose tolerance test, including those at risk of type 1 diabetes. It also invites young people, parents and healthcare workers for interviews.
- Age
- Under 18 years old (up to 17 years). Some interview groups include parents and healthcare workers.
- Sex
- All sexes can join.
- Disease stage
- Cohort 2: positive for two or more islet autoantibodies. Cohort 3: prediabetes. CGM sub-study: confirmed stage 1, 2 or 3 type 1 diabetes. Cohort 1: no disease stage is named.
- Earlier treatment
- People with known clinical diabetes who are on treatment cannot join cohorts 2 and 3.
- Biomarker or test result
- Cohort 2: positive for two or more islet autoantibodies at any time.
Main reasons for not taking part
- Any known haemoglobinopathy (cohorts 1, 2 and the CGM sub-study)
- Cystic fibrosis related diabetes (cohort 1 and the CGM sub-study)
- Known clinical diabetes on treatment (cohorts 2 and 3)
- Non-English speaker
- No recent weight within 3 months and unable to get a new one (cohorts 2 and 3)
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Cohort 1
- Willing and able to give informed consent for participation, or assent with parental consent
- Aged < 18 years old
- Able to consume oral glucose drink within 10 minutes
- Undergoing an OGTT, or consent to have one; Cohort 2
- Positive for two or more islet autoantibodies at any time
- Willing and able to give informed consent for participation, or assent with parental consent
- Aged < 18 years old
- Able to consume oral glucose drink within 10 minutes; CGM sub-study
- Willing and able to give informed consent for participation, or assent with parental consent
- Aged < 18 years old
- Able to consume oral glucose drink within 10 minutes
- Confirmed to have stage 1, 2 or 3 T1D
- Participation in Cohort 1; Qualitative sub-study
- Willing and able to give informed consent for participation, or assent with parental consent Then EITHER
- A young person positive for two or more islet autoantibodies (15 years old and above) at any time, or parent of a young person who has experienced a metabolic test e.g. OGTT OR
- A healthcare professional involved in delivering metabolic testing; Cohort 3
- Prediabetes diagnosis as above
- Willing and able to give informed consent for participation, or assent with parental consent
- Aged < 18 years old
- Able to consume oral glucose drink within 10 minutes
Who cannot take part
- Cystic fibrosis related diabetes
- Known clinical diabetes and on treatment
- Cystic fibrosis related diabetes
- Known clinical diabetes and on treatment
- Cohort 1
- Any known haemoglobinopathy
- Non-English speaker; Cohort 2
- Any known haemoglobinopathy
- Non-English speaker
- No recent weight available (within 3 months of study visit) and unable to obtain new weight measurement; CGM sub-study
- Any known haemoglobinopathy
- Non-English speaker
- Any active skin issue which would prevent the use of a CGM device; Qualitative sub-study
- Non-English speaker; Cohort 3
- Non-English speaker
- No recent weight available (within 3 months of study visit) and unable to obtain new weight measurement
Where in United Kingdom
- Noah's Ark Childrens Hospital for WalesCardiff, United KingdomContact: Anna de CarteretTaking people
- Royal London Barts Health NHS TrustLondon, United KingdomContact: Kevin SamuelsTaking people
- Nottingham Childrens HospitalNottingham, United KingdomContact: Binta BarraTaking people
- John Radcliffe HospitalOxford, United KingdomContact: Rabbi Swaby, BMBSTaking people
About the trial
What the trial wants to find out
Type 1 diabetes (T1D) is a chronic condition, affecting 1 in 490 children under the age of 15 years. It is caused by the immune system damaging the pancreas, the organ which makes insulin. T1D has recognised stages before symptoms develop, providing an opportunity for early diagnosis, education and treatment which may delay the onset of symptoms. Type 2 diabetes (T2D) is also a chronic condition where the body cannot make enough insulin, or cannot respond to the insulin properly. It is usually related to obesity, rather than an immune problem. It is more common in adults, but the early stages often start in childhood (up to 1 in 4 children in some clinics). Like T1D, early detection can delay onset of T2D, or even prevent it altogether. Early diagnosis of T1D or T2D often relies on a test called the oral glucose tolerance test (OGTT), which is commonly used but not well tolerated, possibly because it requires a drip inserted into the vein, and several blood samples taken over 2-3 hours in a healthcare setting. Our study aims to test whether we can do an OGTT using a finger-prick to test glucose, at home. We call this the 'GTT@home'. The finger-prick creates a drop of blood, which is done before and two hours after drinking a sugary drink. We will also explore whether a continuous glucose monitor (CGM), which reads glucose levels through the skin could be an alternative. We plan to recruit 90 children and young people, across two groups to assess the GTT@home. To understand the experiences of those involved in monitoring, we will invite young people, parents and healthcare workers to take part in an interview, to understand the impact of testing to predict clinical T1D. Group 1 will assess the accuracy of measuring glucose from a finger-prick blood test when compared to a blood test from the vein. We will recruit individuals who are having an OGTT as part of a research study, for clinical care or if they have agreed to have an OGTT for this study. Those with T1D will be invited to wear a CGM to explore its use as an additional, practical alternative. Groups 2 and 3 will assess how well the GTT@home test works when done at home and how acceptable it is. This will only be offered to those known to be at risk of T1D. These studies will help us to understand if the GTT@home can be used in routine care.
The 5 groups in the trial
- Cohort 1 (Simultaneous venous and capillary OGTT)
To assess the ability of the capillary OGTT to be a reliable and acceptable alternative to the standard venous OGTT in children, investigators will aim to capture a spread of glucose values across the whole diagnostic range. This will be undertaken in clinical and research settings, led by either a healthcare professional or research nurse. Children undergoing a standard venous OGTT will be invited to complete a capillary OGTT. Both venous and capillary samples will be collected at the same time. Investigators will also invite children with stage 3 (clinical) T1D to capture glucose levels in the hyperglycaemic range. These participants will receive a smaller glucose dose for their OGTT (1g/kg, max dose 75g), to attenuate their glucose rise and allow the comparison of clinically meaningful glucose values. Participants will be asked to complete a questionnaire following the OGTT to obtain information about acceptability.
- Cohort 2 (Capillary OGTT at home)
In this cohort (running concurrently alongside cohort 1) investigators aim to assess the acceptability and feasibility of a capillary OGTT device in children and young people with early-stage (known stage 1 or 2) T1D. This will take place in the home of participants, with written and video instructions provided. Children known to be positive for ≥ 2 IAb will be invited to take part and will be sent a capillary OGTT test kit which will include a glucose drink, lancets and instructions (written and video). They will fast overnight (from midnight the night before, for a minimum of 8 hours) before completing a 2-hour OGTT using the test kit and instructions provided. Glucose samples will be collected at 0 and 120 minutes. Participants will be asked to complete a questionnaire following completion of the OGTT, to obtain information about acceptability.
- Cohort 1 (CGM sub-study)
In this sub-study investigators aim to explore the ability of CGM to be an alternative to the standard venous OGTT. A subgroup of participants in cohort 1 with known T1D (stage 1, 2 or 3) will be invited to wear a CGM sensor for up to 10 days, which will be worn during their OGTT, at home during a standard mixed meal and free-living. Whilst wearing the CGM at home, participants will be asked to consume a liquid mixed meal (Ensure Plus, 6ml/kg maximum 360ml, preceded by an 8-hour fast) and complete a 3-day food diary, by photographing the largest meal of the day to allow estimation of carbohydrate intake (not the same day as the OGTT or liquid mixed meal). Participants will then be asked to complete a questionnaire to obtain information about acceptability.
- Qualitative sub-study
To understand the factors that contribute to uptake of monitoring offered to children at risk of type 1 diabetes, investigators will invite a small number of young people (aged 15-18) and parents to take part in a semi-structured interview. Investigators will also invite healthcare professionals involved in delivering metabolic testing as part of follow-up to take part in semi-structured interviews, to understand their views on the factors which may influence future implementation into clinical care.
- Cohort 3 (Pre-clinical type 2 diabetes)
In this cohort (running concurrently alongside cohort 1) we aim to assess the acceptability and feasibility of a capillary OGTT device in children with pre-clinical T2D at home. This will take place in the home of participants, with written or video instructions provided. For cohort 3, children with raised BMI (≥91st centile) and any marker of insulin resistance: HbA1c 39-47mmol, or known impaired fasting glucose (5.6 - 6.9 mmol/L), or impaired glucose tolerance (7.8 - 11.0 mmol/L), will be invited to take part. They will fast overnight (from midnight the night before, for a minimum of 8 hours) before completing a 2-hour OGTT using the test kit and instructions provided. Participants will be asked to complete a questionnaire following completion of the OGTT, to obtain information about acceptability.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Study to Determine a Capillary Alternative to the Gold Standard Oral Glucose Tolerance Test
- Plain-language title
- Tests a finger-prick glucose test at home for early diabetes checksGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 April 2026